GSK receives recommendation for Bexsero booster dose
The European Medicines Agency recommended adding the option of a Bexsero vaccine booster dose for individuals aged 10 years and older. The change applies to patients who completed primary immunization at least two years earlier.
Key points
- The Committee for Medicinal Products for Human Use (CHMP) backed updating the label for the Bexsero vaccine, which is used to prevent invasive meningococcal disease and is registered in 61 countries.
- On November 10, 2026, five GSK executives, including Lynn Baxter, Julie Brown, David Redfern, Regis Simard, and James Strenner, each acquired 12 company shares under a reward plan at £19.3453 per share.
Recommendation to update Bexsero label
The Committee for Medicinal Products for Human Use (CHMP) backed updating the label for the Bexsero vaccine, which is used to prevent invasive meningococcal disease and is registered in 61 countries. The drug is currently included in 15 national infant and 3 adolescent immunization programs. From 2015 to October 2025, 140 million vaccine doses were shipped.
Other events
On November 10, 2026, five GSK executives, including Lynn Baxter, Julie Brown, David Redfern, Regis Simard, and James Strenner, each acquired 12 company shares under a reward plan at £19.3453 per share.
On November 13, 2026, board member Hal Barron acquired 72 American depositary shares (ADS) at $50.4500 by reinvesting dividends in a pension plan.
What to watch next
The CHMP recommendation is not a final approval. Changes require an official European Commission decision and subsequent adaptation of national immunization programs, which will determine the actual impact on vaccine usage.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow GSK
A notification in your browser or on your phone when we publish about GSK. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
